<\/p>\n
CVS Health (CVS) is targeting the earliest point in a customer’s weight-loss drug decision: the first consultation.<\/p>\n
On Aug. 5, the company dropped the cash price of a MinuteClinic online weight-loss visit to $29, with no membership and no monthly fee.\u00a0<\/p>\n
That is the lowest sticker price in the retail telehealth market for a GLP-1 evaluation.<\/p>\n
CVS also reported a quarter that beat expectations and raised its full-year outlook the same day \u2014 but the $29 visit is the detail worth understanding for anyone holding CVS Health or watching the stock.<\/p>\n
It shows how CVS plans to grow, and where that growth plan is most exposed.<\/p>\n
CVS uses $29 visit to undercut Hims, Ro, and Noom<\/p>\n
Digital-first weight-loss platforms such as Hims & Hers, Ro, and Noom typically charge monthly membership or consultation fees that run from about $40 to well over $100.\u00a0<\/p>\n
CVS priced its clinician visit at $29 and removed the recurring fee entirely.<\/p>\n
The $29 covers the clinical evaluation by a licensed clinician who can prescribe GLP-1 therapy when it fits. It does not cover lab work or the medication.<\/p>\n
That distinction matters for how CVS makes money here, and it points to the real strategy.<\/p>\n
How CVS turns a cheap visit into pharmacy revenue<\/p>\n
A $29 visit does not make CVS much money on its own. The prescription it leads to does.<\/p>\n
CVS runs about 9,000 pharmacies. When a MinuteClinic clinician writes a GLP-1 prescription, CVS can fill it in its own stores for same-day pickup.<\/p>\n
GLP-1 drugs are taken monthly for long stretches, so each new patient can become recurring pharmacy revenue.<\/p>\n
More Healthcare Stocks:<\/p>\n
JPMorgan resets LLY stock target on drug demandGoldman Sachs says one number will move Eli Lilly stockUnitedHealth’s earnings comeback hides a risk Wall Street can’t price<\/p>\n
Telehealth startups usually route prescriptions to third-party pharmacies. CVS keeps the whole path inside its own network, from the online visit to the counter.<\/p>\n
That is the point of the low price. It is a customer-acquisition tool for the pharmacy business, not a profit center by itself.<\/p>\n
CVS cut its MinuteClinic weight-loss consultation fee to $29 as part of a new collaboration with Eli Lilly.<\/p>\n
JHVEPhoto / Getty Images<\/p>\n
The Eli Lilly deal that makes the strategy work<\/p>\n
The price cut arrived alongside a new collaboration with Eli Lilly (LLY), and the timing was deliberate.<\/p>\n
Through the deal, eligible patients will see transparent pricing for Zepbound and Foundayo, two of Lilly’s weight-loss therapies, inside the CVS Health app, Quartz reported.\u00a0<\/p>\n
Same-day pickup at CVS pharmacies starts in the early fourth quarter of 2026.<\/p>\n
Related: UBS strongly resets Lilly stock target<\/p>\n
For self-pay patients, CVS pairs the visit with manufacturer savings that bring select GLP-1 medications down to as low as $149 a month with a coupon, according to according to CVS.\u00a0<\/p>\n
Standard cash prices for these drugs often top $1,000.<\/p>\n
Lilly has the supply to back this up. Zepbound and Mounjaro generated a combined $14.9 billion last quarter, Benzinga reported.<\/p>\n
CVS is positioning itself as the cheapest starting point into that demand.<\/p>\n
Why the quarter was strong but the stock still fell<\/p>\n
CVS delivered a strong quarter and the market still sold the stock. Both facts are true, and they explain each other.<\/p>\n
The company posted adjusted earnings of $2.58 a share, upmore than 40% from a year earlier, on revenue of $106.1 billion, CNBC reported.\u00a0<\/p>\n
Health Services revenue grew 11.5% to nearly $52 billion.<\/p>\n
CVS also raised full-year adjusted earnings guidance to $7.90 to $8.10 a share, up from $7.30 to $7.50.<\/p>\n
However, shares still fell more than 6% in morning trading.\u00a0<\/p>\n
The trigger was CVS management’s warning about membership declines at Caremark, its pharmacy benefit manager, CNBC noted<\/p>\n
So investors got a beat on earnings and a caution flag on future PBM volume in the same report. The weight-loss push does not fix that concern.<\/p>\n
What CVS investors should watch next<\/p>\n
The $29 offer only pays off if a few things go right.<\/p>\n
Here is what needs to happen for the strategy to add real value:<\/p>\n
GLP-1 read-through for CVSEnough $29 visits convert into filled prescriptions inside CVS pharmaciesLilly’s supply keeps up so patients can actually get the drug they were prescribedCaremark membership pressure does not erase the pharmacy gains<\/p>\n
Supply is the biggest risk. Demand for brand-name GLP-1 drugs has surpassed production, and a customer who pays $29 and cannot get the prescription is a lost customer.<\/p>\n
There is also a broader question. CVS still faces scrutiny of its PBM business and cost pressure inside its Aetna insurance unit.<\/p>\n
That is why the stock reaction stayed cautious even after a raise.<\/p>\n
The bottom line for CVS stock<\/p>\n
The $29 visit fee makes CVS the price leader at the entry point of the fastest-growing category in consumer healthcare.<\/p>\n
Paired with the Eli Lilly deal and 9,000 pharmacies, it gives CVS a direct, low-cost path to capture GLP-1 patients before rivals do.<\/p>\n
It does not solve the Caremark membership worry or the Aetna cost pressure that weighed on the stock this week.<\/p>\n
For investors, watch how many of those cheap visits turn into filled prescriptions over the next two quarters.<\/p>\n
Also, size any position to your own risk tolerance, because even a strong quarter did not stop this stock from falling.<\/p>\n
Related: UnitedHealth CFO sends stark warning after earnings<\/p>\n
#Healthcare #giant #slashes #key #consultation #fee #beat #rivals<\/p>\n","protected":false},"excerpt":{"rendered":"
CVS Health (CVS) is targeting the earliest point in a customer’s weight-loss drug decision: the…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[259],"tags":[1659,9581,2308,1356,1485,634,5065,10270],"_links":{"self":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/13118"}],"collection":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13118"}],"version-history":[{"count":0,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/13118\/revisions"}],"wp:attachment":[{"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}